ALK
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib (NCT07374614) | Peking University Shenzhen Hospital | 2026-01-31 |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC (NCT07235306) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-12-01 |
| The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors (NCT06772610) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-03-15 |
| The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study (NCT06652555) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-10-30 |
Track ALK automatically
Every clearance here is in the API, with alerts when new ones post.